280 related articles for article (PubMed ID: 21464100)
1. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
Czernichow S; Knol MJ; Fezeu L; Grobbee DE
Eur J Prev Cardiol; 2012 Jun; 19(3):484-9. PubMed ID: 21464100
[TBL] [Abstract][Full Text] [Related]
2. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
Hemo B; Endevelt R; Porath A; Stampfer MJ; Shai I
Diabetes Res Clin Pract; 2011 Nov; 94(2):269-75. PubMed ID: 21907442
[TBL] [Abstract][Full Text] [Related]
3. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
4. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
[TBL] [Abstract][Full Text] [Related]
6. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
7. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
8. National trends in the use and costs of anti-obesity medications in England 1998-2005.
Srishanmuganathan J; Patel H; Car J; Majeed A
J Public Health (Oxf); 2007 Jun; 29(2):199-202. PubMed ID: 17494061
[TBL] [Abstract][Full Text] [Related]
9. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.
Schwartz SM; Bansal VP; Hale C; Rossi M; Engle JP
Obesity (Silver Spring); 2008 Mar; 16(3):623-9. PubMed ID: 18239553
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of orlistat: results of a prescription-event monitoring study.
Acharya NV; Wilton LV; Shakir SA
Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
Erdmann J; Lippl F; Klose G; Schusdziarra V
Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
[TBL] [Abstract][Full Text] [Related]
12. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
13. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
Chou KM; Huang BY; Fanchiang JK; Chen CH
Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
[TBL] [Abstract][Full Text] [Related]
15. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines.
Rissanen A; Lean M; Rössner S; Segal KR; Sjöström L
Int J Obes Relat Metab Disord; 2003 Jan; 27(1):103-9. PubMed ID: 12532161
[TBL] [Abstract][Full Text] [Related]
17. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
18. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
[TBL] [Abstract][Full Text] [Related]
19. Orlistat for obesity: benefits beyond weight loss.
Hsieh CJ; Wang PW; Liu RT; Tung SC; Chien WY; Chen JF; Chen CH; Kuo MC; Hu YH
Diabetes Res Clin Pract; 2005 Jan; 67(1):78-83. PubMed ID: 15620437
[TBL] [Abstract][Full Text] [Related]
20. Orlistat.
Wong NN; Cheng-Lai A
Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
